Invivyd, Inc. · NASDAQ:IVVD
Invivyd — J.P. Morgan 41st Annual Healthcare Conference 2023
10 slides from Invivyd's conference presentation, Jan 9, 2023
Slide 1: J.P. Morgan 41st Annual Healthcare Conference January 2023
J.P. Morgan 41st Annual Healthcare Conference January 2023 Exhibit 99.1
Slide 2: Forward Looking Statements
1 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words such as “may,” “will,”
Slide 3: Overview of Invivyd
Overview of Invivyd Antibodies designed to protect humanity from serious viral diseases Initial focus on COVID-19 with antibodies designed towards addressing variants of concern Growing number of antibodies aiming to overcome the challenges of viral evolution, starting in COVID-19 Plans to expand in
Slide 4: Invivyd in action: approach to selection of next generation COVID-19 product candidates
INVIVYD in action: approach to SELECTION OF next generation covid-19 product CANDIDATES Continuous monitoring of viral evolution coupled with rapid antibody discovery and engineering to address the evolving SARS-CoV-2 threat Mine human antibody repertoires induced following contemporary SARS-CoV-2 e
Slide 5: NVD200: A Combination Approach of Two Antibodies Targeting Distinct Epitopes
NVD200: A Combination Approach of two antibodies Targeting Distinct Epitopes NVD200 = VYD224 + VYD222 (Re-engineered ADG20) VYD224 VYD222 Designed for: High potency Lack of polyreactivity Long half-life Developability Patient and health system ease of use Potential to resist escape Target non-overla
Slide 6: Robust Pipeline of Antibodies for Treatment and Prevention of Viral Diseases
Robust Pipeline of Antibodies for Treatment and Prevention of Viral Diseases 5 Investigational therapies are not approved for use by regulatory authorities. The safety and efficacy of pipeline candidates have not been established. PROGRAMS PLATFORM INDICATION(S) DEVELOPMENT STATUS STATUS DISCOVERY I
Slide 7: Demonstrated development success with Adintrevimab: from IND to topline data in 16 months
DEMONSTRATED development SUCCESS with Adintrevimab: from ind to topline data in 16 months 6 Late Q4 2020 1H 2021 2H 2021 Adintrevimab IND Enabling & Submission Phase 1 First in Human 1st Subject Dosed Adintrevimab Topline Data Q1 2022 EVADE (prevention) Ph2/3 Enrollment Initiated (US) STAMP (treatme
Slide 8: FDA-EMA Joint Working Session on Novel Strategies for COVID-19 Antibody Development
FDA-EMA Joint Working Session ON Novel STRATEGIES FOR COVID-19 Antibody Development IN THE FACE OF rapidly evolving vARIants – DecEMBER 20221,2 7 Multi-sponsor industry presentation provided scientific rationale for the use of surrogate clinical markers to support the development of next-generation
Slide 9: Cash Position
Cash Position: Cash, cash equivalents and marketable securities were $419 million as of September 30, 2022 company well capitalized to develop lead candidate & additional pipeline assets *Includes vested and unvested outstanding options as of September 30, 2022; excludes treasury stock Planned cash
Slide 10: Thank You
—INVIVYD t THANK YOU
Invivyd — J.P. Morgan 41st Annual Healthcare Conference 2023 on 6ix